Results 61 to 70 of about 1,302,625 (339)
Human Vaccines & Immunotherapeutics, 2018 Despite high vaccination coverage worldwide, pertussis has re-emerged in many countries. This randomized, controlled, observer-blind phase I study and extension study in Belgium (March 2012–June 2015) assessed safety and immunogenicity of investigational
Geert Leroux-Roels +22 more
doaj +1 more source
npj Vaccines, 2020 It has been proven challenging to conduct traditional efficacy trials for Ebola virus (EBOV) vaccines. In the absence of efficacy data, immunobridging is an approach to infer the likelihood of a vaccine protective effect, by translating vaccine ...
Ramon Roozendaal +28 more
doaj +1 more source
, 2013 Since vaccination was documented by Edward Jenner in 1798, it has become the most successful means of preventing infectious diseases, saving millions of lives every year. However, application of vaccines is currently not limited to the prevention of infectious diseases.
Jiskoot, W. +2 more
openaire +4 more sources
Vaccines, Vaccination, and Vaccinology [PDF]
The Journal of Infectious Diseases, 2003 Although the demonstration in 1796 by Edward Jenner that vaccinia virus could protect against smallpox was epochal, he was following the path opened by the ancients who had used the smallpox virus itself in the practice of variolation. The work of Louis Pasteur on chicken cholera opened the way to vaccine development in the laboratory.
openaire +3 more sources
Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?
Molecular Oncology, EarlyView.Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley +1 more source
Preclinical evaluation of a chemically detoxified pneumolysin as pneumococcal vaccine antigen
Human Vaccines & Immunotherapeutics, 2017 The use of protein antigens able to protect against the majority of Streptococcus pneumoniae serotypes is envisaged as stand-alone and/or complement to the current capsular polysaccharide-based pneumococcal vaccines.
Philippe Hermand +6 more
doaj +1 more source
Molecular Oncology, EarlyView.Carcinoma‐associated fibroblasts (CAFs) in tumors influence cancer progression. We identified endoglin (ENG) as a key factor in TGF‐β signaling in myofibroblastic CAFs (myCAFs), linked to poor breast cancer outcomes. Inhibiting ENG on myCAFs suppressed the TGF‐β‐Smad2/3 pathway, reducing primary tumor growth and metastasis.
Shoki Okubo +11 more
wiley +1 more source
Human Vaccines & Immunotherapeutics, 2021 The etiology of intussusception (IS), a serious gastrointestinal obstruction, remains unclear. Limited evidence suggests a role for viral infection. We investigated the risk of IS after rotavirus gastroenteritis (RV GE) in the first year of life. In this
Corinne Willame +4 more
doaj +1 more source
A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson
Human Vaccines & Immunotherapeutics, 2022 The novel coronavirus outbreak was declared a pandemic in March 2020. We are reviewing the COVID-19 vaccines authorized for use in the United States by discussing the mechanisms of action, administration, side effects, and efficacy of vaccines developed ...
Rikin Patel +4 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh +5 more
wiley +1 more source